All Oncology News

The OncLive® News page includes the latest in clinical oncology news, including breaking regulatory decisions, clinical trial findings, pivotal and practice-changing data published in academic peer-reviewed journals, and more across solid and hematologic malignancies. Regulatory news includes new drug approvals by the FDA and European Union, priority review and breakthrough therapy designations, and orphan drug and fast track statuses.

BET Inhibitors Plus Sunitinib Induce Early Signs of Clinical Activity in Melanoma Cells

March 23rd 2023

Sunitinib demonstrated synergistic activity with the BET inhibitors JQ1 and NHWD-870 in melanoma cell lines.

Cleveland Clinic Opens New Cancer Center in Abu Dhabi

March 23rd 2023

Cleveland Clinic has opened a new state-of-the-art cancer facility, named the Fatima bint Mubarak Center, at Cleveland Clinic Abu Dhabi.

Emerging Data Offer Alternatives for Patients With Lower-Risk MDS

March 23rd 2023

Frontline treatments that achieve transfusion independence are of paramount importance for patients with lower-risk myelodysplastic syndrome.

Newly Defined Breast Cancer Targets Expand TNBC Treatment Options

March 23rd 2023

Kevin Kalinsky, MD, MS, discusses genetic sequencing in triple-negative breast cancer, the significance of breast cancer tumor board discussions for informing further research and optimizing patient care, and how future directions in breast cancer treatment are building off the current benefits of drugs classes like antibody-drug conjugates.

First-line Zolbetuximab Plus CAPOX Prolongs Survival in CLDN18.2+/HER2– Unresectable Locally Advanced or Metastatic Gastric/GEJ Adenocarcinoma

March 22nd 2023

The addition of zolbetuximab to CAPOX led to a statistically significant improvement in progression-free survival and overall survival compared with placebo plus CAPOX for patients with Claudin-18.2–positive/HER2-negative, unresectable, locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma.

Erdafitinib Elicits Responses in High- and Intermediate-Risk NMIBC Harboring FGFR3/2 Alterations

March 22nd 2023

Siamak Daneshmand, MD, shed light on the phase 2 THOR-2 study evaluating different cohorts of patients with recurrent NMIBC, key findings from cohorts 2 and 3, and how ongoing research seeks to move the needle forward with novel drug delivery methods.

Spotlight on a Rare Hematologic Disorder: Hereditary Hemorrhagic Telangiectasia

March 22nd 2023

Hematologists and oncologists are uniquely poised to aid in the identification of patients with hereditary hemorrhagic telangiectasia and assist in their care, and it is important for the practicing clinician to familiarize oneself with the symptoms of hereditary hemorrhagic telangiectasia to avoid overlooking the diagnosis.

FDA Approves Retifanlimab for Metastatic or Recurrent Locally Advanced Merkel Cell Carcinoma

March 22nd 2023

The FDA has approved retifanlimab-dlwr (Zynyz) for the treatment of adults with metastatic or recurrent locally advanced Merkel cell carcinoma.

Florida Cancer Specialists & Research Institute Television Commercial Recognized with Silver ADDY® Award

March 22nd 2023

A television commercial produced by Florida Cancer Specialists & Research Institute, LLC has been recognized with a Silver ADDY® by the American Advertising Awards, which honors excellence in advertising as judged by creative industry professionals around the world.

Disadvantaged Neighborhoods, Modifiable Chronic Health Conditions Are Associated With Late Deaths in Survivors of Childhood Cancer

March 22nd 2023

Living in a socioeconomically disadvantaged neighborhood or living with modifiable chronic health conditions were associated with an increased risk for death 5 years of more following diagnosis among survivors of childhood cancer, according to findings from a cohort study.

CAR T-Cell Therapy for Multiple Myeloma: Eliminating Disparities Through Accountability

March 22nd 2023

Although the first FDA approval for CAR T-cell therapy in multiple myeloma was 2 years ago, unfortunately, the treatment remains out of reach for too many patients.

MEDI9253 Plus Durvalumab Delivers Little Efficacy in Advanced/Metastatic Solid Tumors

March 22nd 2023

The addition of MEDI9253 to sequential or concurrent treatment with durvalumab failed to elicit more than 1 partial response although proving feasible and safe in patients with advanced or metastatic solid tumors, according to findings from a phase 1 trial.

FDA Approval Sought for Lumisight Optical Imaging Agent to Assist in Intraoperative Breast Cancer Detection

March 21st 2023

A new drug application seeking the approval of Lumisight, an optical imaging agent that detects cancerous tissue during initial lumpectomy to allow for a more complete resection, has been submitted to the FDA.

Second-line Axi-cel Elicits OS Benefit in Relapsed/Refractory LBCL

March 21st 2023

Axicabtagene ciloleucel produced a statistically significant improvement in overall survival compared with standard-of-caretherapy in patients with relapsed/refractory large B-cell lymphoma, according to data from the ZUMA-7 trial.

Adjuvant Pembrolizumab Expands Options for Patients with Resected Stage IB-IIIA NSCLC

March 21st 2023

Luis Paz-Ares, MD, PhD, highlight adverse events to monitor with pembrolizumab in this setting as well as its role in the treatment landscape.

Thomas K. Varghese Jr. MD, MS, MBA, FACS, Named President-Elect of Society of University Surgeons

March 21st 2023

Varghese, known for his innovative research in perioperative care and mentorship to physician-scientists, will become SUS President in February 2024.

FDA Grants Orphan Drug Designation to ISB 1442 for Relapsed/Refractory Multiple Myeloma

March 21st 2023

The FDA has granted an orphan drug designation to ISB 1442, the first-in-class biparatopic 2+1 BEAT® bispecific antibody targeting CD38 and CD47 for the treatment of patients with relapsed/refractory multiple myeloma.

FDA Grants Orphan Drug Designation to FORE8394 for Primary Brain and CNS Malignancies

March 21st 2023

The FDA has granted an orphan drug designation to FORE8394 for the treatment of primary brain and central nervous system malignancies.

HRD-Directed Therapeutics Hold Potential in Breast Cancer, But Challenges Remain

March 21st 2023

Roadblocks such as PARP inhibitor resistance have resulted in an unmet need and uncertain optimal identification concerning patients who would elicit the most benefit from homologous recombination deficiency–directed therapies.

Real-World Analysis Evaluates Inpatient Vs Outpatient CAR T-Cell Therapy Administration in MCL and FL

March 21st 2023

A real-world analysis exploring the outcomes of inpatient vs outpatient administration of CAR T-cell therapy in patients with mantle cell lymphoma and follicular lymphoma demonstrated both similarities and some differences between the 2 patient populations.